{"id":"glucocorticoid-receptor","name":"Glucocorticoid receptor (NR3C1)","symbol":"NR3C1","route":"/targets/glucocorticoid-receptor/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7978","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000113580","uniprot":"https://www.uniprot.org/uniprotkb/P04150/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P04150","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL2034","open-targets":"https://platform.opentargets.org/target/ENSG00000113580","civic":"https://civicdb.org/genes/2908/summary","oncokb":"https://www.oncokb.org/gene/NR3C1","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NR3C1","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=NR3C1","depmap":"https://depmap.org/portal/gene/NR3C1?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000113580-NR3C1","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/2908","omim":"https://www.omim.org/entry/138040"}],"products":[{"id":"dexamethasone","name":"Dexamethasone","status":"approved","modality":"Glucocorticoid","route":"/drugs/dexamethasone/"},{"id":"prednisone","name":"Prednisone","status":"approved","modality":"Glucocorticoid","route":"/drugs/prednisone/"}],"trials":[{"id":"nct04497844","name":"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)","nct":"NCT04497844","phase":"3","status":"active"},{"id":"nct06956170","name":"All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myelo","nct":"NCT06956170","phase":"3","status":"active"},{"id":"nct06868654","name":"China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexame","nct":"NCT06868654","phase":"3","status":"active"},{"id":"nct06868667","name":"Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dex","nct":"NCT06868667","phase":"3","status":"active"},{"id":"keynote-921","name":"KEYNOTE-921","nct":"NCT03834506","phase":"3","status":"negative"},{"id":"nct04446117","name":"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC","nct":"NCT04446117","phase":"3","status":"active"},{"id":"nct02883049","name":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","nct":"NCT02883049","phase":"3","status":"completed"},{"id":"triangle","name":"TRIANGLE","nct":"NCT02858258","phase":"3","status":"positive"},{"id":"nct04649060","name":"Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma","nct":"NCT04649060","phase":"3"},{"id":"nct03151811","name":"A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide","nct":"NCT03151811","phase":"3"},{"id":"nct01517802","name":"A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate","nct":"NCT01517802","phase":"3","status":"completed"},{"id":"aall1231","name":"AALL1231","nct":"NCT02112916","phase":"3","status":"mixed"},{"id":"ahod1331","name":"AHOD1331","nct":"NCT02166463","phase":"3","status":"positive"},{"id":"determination","name":"DETERMINATION","nct":"NCT01208662","phase":"3","status":"positive"},{"id":"nct02257736","name":"An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)","nct":"NCT02257736","phase":"3","status":"active"},{"id":"nct03061812","name":"Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)","nct":"NCT03061812","phase":"3","status":"completed"},{"id":"nct03033511","name":"A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)","nct":"NCT03033511","phase":"3"},{"id":"nct01102426","name":"Aplidin - Dexamethasone in Relapsed/Refractory Myeloma","nct":"NCT01102426","phase":"3","status":"completed"},{"id":"ahl2011","name":"AHL2011","nct":"NCT01358747","phase":"3","status":"positive"},{"id":"calgb-50303","name":"Alliance/CALGB 50303","nct":"NCT00118209","phase":"3","status":"negative"},{"id":"card","name":"CARD","nct":"NCT02485691","phase":"3","status":"positive"},{"id":"cassiopeia","name":"CASSIOPEIA","nct":"NCT02541383","phase":"3","status":"positive"},{"id":"era-223","name":"ERA 223","nct":"NCT02043678","phase":"3","status":"negative"},{"id":"flyer","name":"FLYER","nct":"NCT00278421","phase":"3","status":"positive"},{"id":"maia","name":"MAIA","nct":"NCT02252172","phase":"3","status":"positive"},{"id":"prima-follicular","name":"PRIMA","nct":"NCT00140582","phase":"3","status":"mixed"},{"id":"nct00557193","name":"Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","nct":"NCT00557193","phase":"3","status":"completed"},{"id":"echelon-2","name":"ECHELON-2","nct":"NCT01777152","phase":"3","status":"positive"},{"id":"relevance","name":"RELEVANCE","nct":"NCT01476787","phase":"3","status":"mixed"},{"id":"trog-99-03","name":"TROG 99.03","nct":"NCT00115700","phase":"3","status":"positive"},{"id":"affinity-custirsen","name":"AFFINITY","nct":"NCT01578655","phase":"3","status":"negative"},{"id":"eortc-h10","name":"EORTC/LYSA/FIL H10","nct":"NCT00433433","phase":"3","status":"mixed"},{"id":"firstana","name":"FIRSTANA","nct":"NCT01308567","phase":"3","status":"negative"},{"id":"gallium","name":"GALLIUM","nct":"NCT01332968","phase":"3","status":"positive"},{"id":"hd18","name":"GHSG HD18","nct":"NCT00515554","phase":"3","status":"positive"},{"id":"goya","name":"GOYA","nct":"NCT01287741","phase":"3","status":"negative"},{"id":"ifm-2009","name":"IFM 2009","nct":"NCT01191060","phase":"3","status":"positive"},{"id":"lyma","name":"LyMa","nct":"NCT00921414","phase":"3","status":"positive"},{"id":"proselica","name":"PROSELICA","nct":"NCT01308580","phase":"3","status":"positive"},{"id":"synergy-custirsen","name":"SYNERGY","nct":"NCT01188187","phase":"3","status":"negative"},{"id":"aall0232","name":"AALL0232","nct":"NCT00075725","phase":"3","status":"positive"},{"id":"nct00024167","name":"Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer","nct":"NCT00024167","phase":"3"},{"id":"comet-1","name":"COMET-1","nct":"NCT01605227","phase":"3","status":"negative"},{"id":"quartz","name":"QUARTZ","phase":"3","status":"negative"},{"id":"elm-pc-4-orteronel","name":"ELM-PC 4","nct":"NCT01193244","phase":"3","status":"negative"},{"id":"ts-p04834","name":"Study 3 (rolapitant, moderately emetogenic chemotherapy)","nct":"NCT01500226","phase":"3","status":"positive"},{"id":"cou-aa-302","name":"COU-AA-302","nct":"NCT00887198","phase":"3","status":"positive"},{"id":"ready-dasatinib","name":"READY","nct":"NCT00744497","phase":"3","status":"negative"},{"id":"calgb-90401","name":"CALGB 90401","nct":"NCT00110214","phase":"3","status":"negative"},{"id":"cou-aa-301","name":"COU-AA-301","nct":"NCT00638690","phase":"3","status":"positive"},{"id":"ukallr3","name":"ALL R3 (UKALLR3)","nct":"NCT00967057","phase":"3","status":"positive"},{"id":"tropic","name":"TROPIC","nct":"NCT00417079","phase":"3","status":"positive"},{"id":"jcog9801","name":"JCOG9801","nct":"NCT00145002","phase":"3","status":"mixed"},{"id":"swog-9916","name":"SWOG 9916","nct":"NCT00004001","phase":"3","status":"positive"},{"id":"tax-327","name":"TAX 327","phase":"3","status":"positive"},{"id":"nct06925737","name":"A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)","nct":"NCT06925737","phase":"3","status":"recruiting"},{"id":"nct04529772","name":"A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)","nct":"NCT04529772","phase":"3","status":"active"},{"id":"nct04691804","name":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Ver","nct":"NCT04691804","phase":"3","status":"active"},{"id":"nct06464991","name":"A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)","nct":"NCT06464991","phase":"3","status":"recruiting"},{"id":"nct06413498","name":"A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma","nct":"NCT06413498","phase":"3","status":"active"},{"id":"nct07391657","name":"A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Rela","nct":"NCT07391657","phase":"3","status":"recruiting"},{"id":"nct05455320","name":"A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination Wi","nct":"NCT05455320","phase":"3","status":"active"},{"id":"nct06208150","name":"A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortez","nct":"NCT06208150","phase":"3","status":"active"},{"id":"nct05572515","name":"A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With","nct":"NCT05572515","phase":"3","status":"active"},{"id":"nct03539744","name":"A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) ","nct":"NCT03539744","phase":"3","status":"active"},{"id":"nct05288166","name":"A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)","nct":"NCT05288166","phase":"3","status":"active"},{"id":"nct06679101","name":"A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethas","nct":"NCT06679101","phase":"3","status":"recruiting"},{"id":"nct05438043","name":"A Study of Daratumumab","nct":"NCT05438043","phase":"3","status":"active"},{"id":"nct07225946","name":"A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer","nct":"NCT07225946","phase":"3","status":"recruiting"},{"id":"nct05552222","name":"A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal","nct":"NCT05552222","phase":"3","status":"recruiting"},{"id":"nct07742215","name":"A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)","nct":"NCT07742215","phase":"3","status":"recruiting"},{"id":"nct06091865","name":"A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Pa","nct":"NCT06091865","phase":"3","status":"recruiting"},{"id":"nct05552976","name":"A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants W","nct":"NCT05552976","phase":"3","status":"active"},{"id":"nct05519085","name":"A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Re","nct":"NCT05519085","phase":"3","status":"recruiting"},{"id":"nct06824467","name":"A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Pl","nct":"NCT06824467","phase":"3","status":"recruiting"},{"id":"nct06717347","name":"A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituxi","nct":"NCT06717347","phase":"3","status":"recruiting"},{"id":"nct05623020","name":"A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide","nct":"NCT05623020","phase":"3","status":"recruiting"},{"id":"nct05020236","name":"A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments","nct":"NCT05020236","phase":"3","status":"recruiting"},{"id":"nct06230224","name":"A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell ","nct":"NCT06230224","phase":"3","status":"active"},{"id":"nct05730036","name":"A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Re","nct":"NCT05730036","phase":"3","status":"recruiting"},{"id":"nct06097364","name":"A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemo","nct":"NCT06097364","phase":"3","status":"active"},{"id":"nct06091254","name":"A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy ","nct":"NCT06091254","phase":"3","status":"recruiting"},{"id":"arched","name":"ARCHED","nct":"NCT05820841","phase":"3","status":"active"},{"id":"nct07716228","name":"Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Gemcitabine Combined With Paclitaxel Protein","nct":"NCT07716228","phase":"3","status":"recruiting"},{"id":"cartitude-6","name":"CARTITUDE-6","nct":"NCT05257083","phase":"3","status":"active"},{"id":"nct03777982","name":"Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT","nct":"NCT03777982","phase":"3"},{"id":"nct00033332","name":"Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma","nct":"NCT00033332","phase":"3","status":"completed"},{"id":"nct00316927","name":"Dexamethasone, Aspirin, and Diethylstilbestrol in Treating Patients With Locally Advanced or Metastatic Prostate Cancer","nct":"NCT00316927","phase":"3","status":"completed"},{"id":"euronet-phl-c2","name":"EuroNet-PHL-C2","nct":"NCT02684708","phase":"3","status":"completed"},{"id":"nct03150693","name":"Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia","nct":"NCT03150693","phase":"3","status":"recruiting"},{"id":"nct01117441","name":"International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia","nct":"NCT01117441","phase":"3","status":"completed"},{"id":"nct04270409","name":"Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma","nct":"NCT04270409","phase":"3","status":"active"},{"id":"nct07620574","name":"Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study","nct":"NCT07620574","phase":"3","status":"recruiting"},{"id":"nct06152575","name":"MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other","nct":"NCT06152575","phase":"3","status":"recruiting"},{"id":"mosun-len-mzl","name":"Mosunetuzumab with lenalidomide in relapsed marginal zone lymphoma","nct":"NCT06006117","phase":"3","status":"active"},{"id":"nct04975997","name":"Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants ","nct":"NCT04975997","phase":"3","status":"active"},{"id":"polar-bear","name":"POLAR BEAR","nct":"NCT04332822","phase":"3","status":"active"},{"id":"nct06220032","name":"Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma","nct":"NCT06220032","phase":"3","status":"recruiting"},{"id":"nct06305754","name":"Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, A","nct":"NCT06305754","phase":"3","status":"active"},{"id":"nct03678025","name":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer","nct":"NCT03678025","phase":"3","status":"recruiting"},{"id":"nct06158841","name":"Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refracto","nct":"NCT06158841","phase":"3","status":"active"},{"id":"nct07764978","name":"Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT","nct":"NCT07764978","phase":"3","status":"recruiting"},{"id":"nct06191744","name":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease ","nct":"NCT06191744","phase":"3","status":"active"},{"id":"nct00136084","name":"Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia","nct":"NCT00136084","phase":"3","status":"completed"},{"id":"nct03367572","name":"Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer","nct":"NCT03367572","phase":"3","status":"completed"},{"id":"nct03206671","name":"Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents","nct":"NCT03206671","phase":"3","status":"active"},{"id":"nct06947967","name":"Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype","nct":"NCT06947967","phase":"3","status":"recruiting"},{"id":"nct03706365","name":"A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer","nct":"NCT03706365","phase":"2/3","status":"active"},{"id":"enrich","name":"ENRICH","phase":"2/3","status":"positive"},{"id":"nct04442022","name":"A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Ly","nct":"NCT04442022","phase":"2/3","status":"active"},{"id":"nct07095452","name":"A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lena","nct":"NCT07095452","phase":"2/3","status":"recruiting"},{"id":"nct06616584","name":"Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemoth","nct":"NCT06616584","phase":"2/3","status":"recruiting"},{"id":"nct07213375","name":"High Dose Dexamethasone to Reduce Postoperative Pain After Video-Assisted Thoracoscopic Surgery Lobectomy /Segmentectomy","nct":"NCT07213375","phase":"2/3","status":"recruiting"},{"id":"nct02205762","name":"LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis","nct":"NCT02205762","phase":"2/3","status":"active"},{"id":"nct03668639","name":"Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin","nct":"NCT03668639","phase":"2/3"},{"id":"nct05096663","name":"Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer","nct":"NCT05096663","phase":"2/3","status":"active"},{"id":"nct05673785","name":"A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)","nct":"NCT05673785","phase":"2","status":"active"},{"id":"nct04980222","name":"A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma","nct":"NCT04980222","phase":"2","status":"active"},{"id":"nct05663866","name":"Premedication to Reduce Amivantamab Associated Infusion Related Reactions","nct":"NCT05663866","phase":"2","status":"active"},{"id":"nct03431350","name":"A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer","nct":"NCT03431350","phase":"2","status":"active"},{"id":"nct02963493","name":"A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","nct":"NCT02963493","phase":"2","status":"completed"},{"id":"nct01700946","name":"Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma","nct":"NCT01700946","phase":"2","status":"completed"},{"id":"ptld-1","name":"PTLD-1","nct":"NCT00590447","phase":"2","status":"positive"},{"id":"nct00057811","name":"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma","nct":"NCT00057811","phase":"2","status":"completed"},{"id":"smile-enktl","name":"SMILE","phase":"2","status":"positive"},{"id":"nct06890884","name":"A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)","nct":"NCT06890884","phase":"2","status":"recruiting"},{"id":"nct07553988","name":"A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer","nct":"NCT07553988","phase":"2","status":"active"},{"id":"nct07005154","name":"A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer","nct":"NCT07005154","phase":"2","status":"recruiting"},{"id":"nct02960022","name":"A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study","nct":"NCT02960022","phase":"2","status":"active"},{"id":"nct03314181","name":"A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractor","nct":"NCT03314181","phase":"2","status":"active"},{"id":"nct04133636","name":"A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Mul","nct":"NCT04133636","phase":"2","status":"active"},{"id":"nct06979596","name":"A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)","nct":"NCT06979596","phase":"2","status":"recruiting"},{"id":"nct04414475","name":"A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refrac","nct":"NCT04414475","phase":"2","status":"recruiting"},{"id":"nct05406401","name":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)","nct":"NCT05406401","phase":"2","status":"active"},{"id":"nct05283720","name":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neopl","nct":"NCT05283720","phase":"2","status":"active"},{"id":"nct07227311","name":"A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Mult","nct":"NCT07227311","phase":"2","status":"recruiting"},{"id":"nct06425302","name":"A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma","nct":"NCT06425302","phase":"2","status":"active"},{"id":"nct07284758","name":"A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma","nct":"NCT07284758","phase":"2","status":"recruiting"},{"id":"nct05704049","name":"A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory","nct":"NCT05704049","phase":"2","status":"active"},{"id":"nct07537660","name":"Auricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Gemcitabine Plus Paclitaxel","nct":"NCT07537660","phase":"2","status":"recruiting"},{"id":"nct07432399","name":"Effect of Perioperative Lidocaine or High-Dose Dexamethasone on Immune Response in Colon Cancer Surgery (PILDI Study)","nct":"NCT07432399","phase":"2","status":"recruiting"},{"id":"nct02890602","name":"Erythropoietin for Management of Anemia Caused by Chemotherapy","nct":"NCT02890602","phase":"2","status":"completed"},{"id":"nct05727163","name":"FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutat","nct":"NCT05727163","phase":"2","status":"recruiting"},{"id":"nct05286814","name":"PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarc","nct":"NCT05286814","phase":"2","status":"recruiting"},{"id":"nct06788912","name":"Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)","nct":"NCT06788912","phase":"2","status":"active"},{"id":"nct07018050","name":"Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma","nct":"NCT07018050","phase":"2","status":"recruiting"},{"id":"nct02899052","name":"Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)","nct":"NCT02899052","phase":"2","status":"active"},{"id":"nct02773030","name":"A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple","nct":"NCT02773030","phase":"1/2","status":"active"},{"id":"nct07150104","name":"Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants Wi","nct":"NCT07150104","phase":"1/2","status":"active"},{"id":"nct07150091","name":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM","nct":"NCT07150091","phase":"1/2","status":"active"},{"id":"nct04973605","name":"A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Darat","nct":"NCT04973605","phase":"1/2","status":"recruiting"},{"id":"nct05583617","name":"A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma","nct":"NCT05583617","phase":"1/2","status":"recruiting"},{"id":"nct06689163","name":"A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone","nct":"NCT06689163","phase":"1/2","status":"recruiting"},{"id":"nct05067140","name":"A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer","nct":"NCT05067140","phase":"1/2","status":"active"},{"id":"nct06564038","name":"A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies","nct":"NCT06564038","phase":"1/2","status":"recruiting"},{"id":"nct07124936","name":"A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma","nct":"NCT07124936","phase":"1/2","status":"recruiting"},{"id":"nct06568094","name":"A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer","nct":"NCT06568094","phase":"1/2","status":"recruiting"},{"id":"nct06953960","name":"A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma ","nct":"NCT06953960","phase":"1/2","status":"recruiting"},{"id":"nct06892522","name":"A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-spe","nct":"NCT06892522","phase":"1/2","status":"recruiting"},{"id":"nct03989414","name":"A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Tre","nct":"NCT03989414","phase":"1/2","status":"active"},{"id":"nct06988488","name":"A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatama","nct":"NCT06988488","phase":"1/2","status":"recruiting"},{"id":"nct05201248","name":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Th","nct":"NCT05201248","phase":"1/2","status":"active"},{"id":"nct05319730","name":"A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)","nct":"NCT05319730","phase":"1/2","status":"recruiting"},{"id":"nct05372354","name":"A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed ","nct":"NCT05372354","phase":"1/2","status":"recruiting"},{"id":"nct04300556","name":"A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types","nct":"NCT04300556","phase":"1/2","status":"recruiting"},{"id":"nct05714839","name":"A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatme","nct":"NCT05714839","phase":"1/2","status":"recruiting"},{"id":"nct06106945","name":"AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma","nct":"NCT06106945","phase":"1/2","status":"recruiting"},{"id":"nct07730515","name":"Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma","nct":"NCT07730515","phase":"1/2","status":"recruiting"},{"id":"nct04126200","name":"Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple","nct":"NCT04126200","phase":"1/2","status":"active"},{"id":"nct07387926","name":"Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)","nct":"NCT07387926","phase":"1/2","status":"recruiting"},{"id":"nct04623541","name":"Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome","nct":"NCT04623541","phase":"1/2","status":"active"},{"id":"nct04663347","name":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","nct":"NCT04663347","phase":"1/2","status":"active"},{"id":"nct06087653","name":"Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)","nct":"NCT06087653","phase":"1/2","status":"recruiting"},{"id":"nct02343042","name":"Selinexor and Backbone Treatments of Multiple Myeloma Patients","nct":"NCT02343042","phase":"1/2","status":"recruiting"},{"id":"nct04947189","name":"Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer","nct":"NCT04947189","phase":"1/2","status":"recruiting"},{"id":"nct04068597","name":"Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies","nct":"NCT04068597","phase":"1/2","status":"recruiting"},{"id":"nct06353386","name":"Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)","nct":"NCT06353386","phase":"1/2","status":"recruiting"},{"id":"nct04542824","name":"Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)","nct":"NCT04542824","phase":"1/2","status":"active"}],"pathways":[],"companies":[],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}